Healthcare Equipment and Supplies
Company Overview of Bausch & Lomb Incorporated
Bausch & Lomb Incorporated produces eye care products. The company offers contact and hydrophobic acrylic intraocular lenses; contact lens care, dry eye, allergy/redness relief, pharmaceutical, and surgical products; and eye vitamins and vision accessories. It also offers contract manufacturing services for sterile and non-sterile solutions, suspensions, ointments, gels, creams, nasals, and injectables. The company was formerly known as Bausch & Lomb Optical Company and changed its name to Bausch & Lomb Incorporated in March 1960. Bausch & Lomb Incorporated was founded in 1853 and is based in Rochester, New York. It has additional offices in Argentina, Australia, Austria, Belgium, Bulgaria, ...
1400 North Goodman Street
Rochester, NY 14609
Founded in 1853
Key Executives for Bausch & Lomb Incorporated
President and Chief Financial Officer
President of Asia-Pacific
Corporate Vice President and Global President of Pharmaceuticals Business
Corporate Vice President and President of Latin America Operations
Global President of Vision Care Business
Compensation as of Fiscal Year 2014.
Bausch & Lomb Incorporated Key Developments
Nicox to Co-Promote Latanoprostene Bunod in US with Bausch + Lomb
Aug 11 14
Nicox SA announced its decision to exercise rights to co-promote latanoprostene bunod in the US with Bausch + Lomb. According to the terms of a licensing agreement signed by the two companies in 2010, Nicox retains the possibility to co-promote latanoprostene bunod in the US.
Bausch & Lomb Inc. Wins $16.69 Million Federal Contract
Jul 25 14
Bausch & Lomb Inc. won a $16,689,720.96 federal contract from the U.S. Department of Veterans Affairs' National Acquisition Center, Chicago, for PreserVision Areds 2 Formula and PreserVision Areds Lutein.
Bausch + Lomb's VICTUS(R) Femtosecond Laser Platform Receives 510(K) Clearance from FDA for Lens Fragmentation Procedure
Jul 17 14
Valeant Pharmaceuticals International Inc. announced that its wholly owned subsidiary, Bausch + Lomb has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VICTUS(R) Femtosecond Laser Platform for laser-assisted lens fragmentation during cataract surgery. The fragmentation procedure, which follows a capsulotomy, uses the femtosecond laser to split the cataractous lens into sections. This is followed by phacoemulsification for cataract removal. The VICTUS platform offers a number of different lens fragmentation patterns depending on the cataract grade and user preference.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|